Gut bacteria directly inject proteins into human cells, shaping immune responses

For decades, scientists have treated the bacteria living in your gut as mostly passive—residents that either help or harm you, but don't actively reach into your cells and reshape how your body works. A discovery published this month in Nature Microbiology upends that picture. Researchers at Helmholtz Munich, working with teams from Ludwig Maximilians University, Aix Marseille University, Inserm, and international collaborators, have found that harmless, everyday gut bacteria possess microscopic syringe-like structures capable of injecting proteins directly into human cells. Until now, these injection systems were thought to exist only in dangerous pathogens like Salmonella. They do not.

The finding matters because it reveals a previously invisible channel of communication between the microbiome and the human immune system—one that appears to actively shape how your body responds to infection and inflammation. "This fundamentally changes our view of commensal bacteria," says Pascal Falter-Braun, director of the Institute for Network Biology at Helmholtz Munich and a corresponding author of the study. "It shows that these non-pathogenic bacteria are not just passive residents but can actively manipulate human cells by injecting their proteins into our cells." The bacteria accomplish this through structures called type III secretion systems, biological machinery that functions like a molecular needle, piercing the cell membrane and delivering cargo directly into the cytoplasm.

To understand what these bacterial proteins actually do once inside human cells, the research team mapped more than a thousand direct interactions between bacterial effector proteins and human proteins. The scale of this mapping exercise is significant—it created a large-scale network showing which human pathways the bacterial proteins target. The pattern that emerged was striking: the bacterial proteins preferentially zeroed in on human systems involved in immune regulation and metabolism. Laboratory experiments confirmed that these proteins can modulate key immune signaling pathways, including one called NF-κB and the broader cascade of cytokine responses. Cytokines are the chemical messengers that coordinate immune activity and, critically, prevent the immune system from overreacting in ways that trigger autoimmune disease. The connection is not abstract: inhibiting tumor necrosis factor, a specific cytokine, is already a standard treatment for Crohn's disease, an inflammatory bowel disorder.

This is where the research points toward human disease. The team discovered that genes encoding these bacterial effector proteins are enriched in the gut microbiomes of patients with Crohn's disease. In other words, people with this chronic intestinal inflammation carry more of these protein-injecting bacteria than healthy controls do. The finding suggests a potential mechanism—a concrete molecular pathway—that could explain why changes in gut bacteria composition have long been associated with inflammatory bowel disease. For years, researchers knew the correlation existed but could not explain how it worked. Now they have a candidate answer: certain bacteria are actively delivering proteins into intestinal cells in ways that may tip the immune system toward chronic inflammation.

Veronika Young, first author of the study alongside Bushra Dohai, framed the research goal plainly: "By systematically mapping direct protein–protein interactions between bacterial and human cells, we can now suggest molecular mechanisms behind these associations." The work shifts the field from observing that microbiome changes correlate with disease toward understanding why those changes matter at the molecular level. It also raises a deeper question that future research will need to address: did these injection systems evolve originally to help bacteria coexist peacefully with their human hosts, or did pathogens develop them first and commensal bacteria later acquire the same capability? The answer may reshape how scientists think about the evolutionary relationship between humans and the trillions of microorganisms living inside us.

The next phase of research will focus on how individual bacterial proteins function in specific tissues and disease contexts, with the ultimate goal of translating these findings into new strategies for preventing and treating inflammatory diseases. For patients with Crohn's disease and other conditions linked to microbiome dysfunction, the implications are significant: understanding the precise molecular mechanisms by which bacteria influence immune cells opens the door to interventions far more targeted than simply trying to change which bacteria are present.